MedTrace Logo

MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma

NCT02514824 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2020-12-29

Study results available
· View outcomes & findings →

Summary

This research study is studying a targeted therapy as a possible treatment for merkel cell carcinoma.

\- The name of the study intervention involved in this study is: MLN0128.

Conditions

Interventions

DRUG

MLN0128

Investigational mTOR kinase inhibitor

Sponsors & Collaborators

Principal Investigators

  • Robert Haddad, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-04-30
Completion
2017-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02514824 on ClinicalTrials.gov